Home » Topics » Conferences

Conferences
RSS

Prostate cancer immunotherapeutic evaluated in preclinical and clinical trials

April 6, 1998

RS-100975, a prostate-selective alpha-blocker in vitro

April 6, 1998

The alpha1L-adrenoceptor: a new target for BPH therapy

April 6, 1998

Orally active thrombin inhibitor discovered at Pfizer shows good tolerance in phase I

April 6, 1998

Selective PDE IV/TNF-alpha inhibitors focus of research at Yamanouchi

April 6, 1998

Highly potent GH secretatogues discovered by Merck & Co.

April 6, 1998

TER-199 resistance-modulating mechanisms explored

April 6, 1998

CGP-60474: selective protein tyrosine kinase inhibitor for cancer

April 3, 1998

Dual-action agent for BPH developed at Zeria

April 3, 1998

Abbott/TAP discover safer LHRH antagonists

April 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...